Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line

Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat

August 8, 2016 6:53 AM EDT

Mizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More

Teva (TEVA): Soft 2Q Underscores Need For Actavis - Piper Jaffray

August 5, 2016 9:03 AM EDT

Piper Jaffray analyst David Amsellem bumped his price target on Teva Pharma (NYSE: TEVA) to $57.00 (from $55.00) but maintained a Neutral rating following Q2 results.

Amsellem commented, "Teva reported 2Q16 non-GAAP diluted EPS of $1.25 on revenue of $5.04B; recall that the company pre-announced... More

Oppenheimer Downgrades Teva Pharma (TEVA) to Perform

August 5, 2016 7:27 AM EDT

Oppenheimer downgraded Teva Pharma (NYSE: TEVA) from Outperform to Perform and removed its price target (prior $72.00).

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $55.45 yesterday.

... More